Astellas Pharma Inc 2025 IR
The report outlines Astellas' strategic progress and financial performance for the fiscal year ending March 31, 2025. The company achieved record-high revenue of ¥1,912.3 billion and core operating profit of ¥392.4 billion, driven by the strong performance of its strategic brands. Key highlights include achieving clinical proof of concept for the KRAS G12D degrader ASP3082 and launching a new patient-centric operating model. Additionally, the report details Astellas' sustainability initiatives, including efforts to visualize the social impact of its Access to Health programs and its progress toward net-zero greenhouse gas emissions.
Company: Astellas Pharma Inc
Sector: Health Care
Country: Japan
Year: 2025
Type: IR
Pages: 113
Astellas Pharma Inc
Integrated Report
The report outlines Astellas' strategic progress and financial performance for the fiscal year ending March 31, 2025. The company achieved record-high revenue of ¥1,912.3 billion and core operating profit of ¥392.4 billion, driven by the strong performance of its strategic brands. Key highlights include achieving clinical proof of concept for the KRAS G12D degrader ASP3082 and launching a new patient-centric operating model. Additionally, the report details Astellas' sustainability initiatives, including efforts to visualize the social impact of its Access to Health programs and its progress toward net-zero greenhouse gas emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Apr 1, 2024 - Mar 31, 2025
Fiscal Year
2025
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees